Spathodea Campanulata: Een antidiabetisch geneesmiddel?

Author Biographies

Gert Laekeman, Instituut Farmaceutische Wetenschappen KU-Leuven

Pharmacology

Gaspard Niyonzima, Departement Farmaceutische Wetenschappen UIA Antwerpen

Pharmacology

Simon Scharpe, Departement Farmaceutische Wetenschappen UIA Antwerpen

Pharmacology

Arnold Vlietinck, Departement Farmaceutische Wetenschappen UIA Antwerpen

Pharmacology

Tony Mets, Faculteit Geneeskunde VUB Brussel

Medicine

Main Article Content

Gert Laekeman (Instituut Farmaceutische Wetenschappen KU-Leuven)

Gaspard Niyonzima (Departement Farmaceutische Wetenschappen UIA Antwerpen)

Simon Scharpe (Departement Farmaceutische Wetenschappen UIA Antwerpen)

Arnold Vlietinck (Departement Farmaceutische Wetenschappen UIA Antwerpen)

Tony Mets (Faculteit Geneeskunde VUB Brussel)

Published Jul 6, 1992

Abstract

Decoctions of the stem back of Spathodea campanulata (SC) are currently used in Rwanda to treat insulin- and non insulin-dependent diabetics. In order to confirm and further examine hypoglycemic activity of this plant we set up a research project with as final objective a possible standardisation of Spathodea in antidiabetic therapy in Rwanda. 


Up to now we were able to confirm the blood sugar lowering effect of SC in hyperglycemic mice (Iiyperglycemia provoked by streptozotocin = SZ). Also hyperglycemia in glucose loaded mice (glucose tolerance test = GTT) could be tempered by SC. Despite these clearcut hypoglycemic activity, no rise of insulin was seen in the SC treated mice. Tlie activity must be due to some other mechanism of action.


Tlie search for active principles did not lead to satisfying results up to now. We have only indirect evidence for the presence of sugar-like compounds, as SC decoctions enhance the glycemia transiently.


Some hypotheses are formulated with regard to mechanisms of action and active compounds of SC. These aspects will guide future research. 


Article Sidebar